

## Head injury: assessment and early management (update)

[N] Evidence reviews for identification of hypopituitarism (when to investigate)

*NICE guideline <number>*

*Evidence reviews underpinning recommendations x to y and research recommendations in the NICE guideline*

*September 2022*

*Draft for consultation*

*These evidence reviews were developed by the Guideline Development Team NGC*



## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© NICE 2023. All rights reserved. [Subject to Notice of rights](#).

## Contents

<b>1 Identification of hypopituitarism (when to investigate)</b> .....	<b>5</b>
1.1 Review question .....	5
1.1.1 Introduction.....	5
1.1.2 Summary of the protocol.....	5
1.1.3 Methods and process .....	7
1.1.4 Effectiveness evidence .....	8
1.1.5 Summary of studies included in the effectiveness evidence .....	8
1.1.6 Summary of the effectiveness evidence .....	8
1.1.7 Economic evidence .....	9
1.1.8 Summary of included economic evidence.....	10
1.1.9 Economic model.....	10
1.1.11 Evidence statements .....	11
1.1.12 The committee's discussion and interpretation of the evidence .....	11
<b>References</b> .....	<b>12</b>
<b>Appendices</b> .....	<b>13</b>
<b>Appendix A – Review protocols</b> .....	<b>13</b>
<b>Appendix B – Literature search strategies</b> .....	<b>28</b>
<b>Appendix C – Effectiveness evidence study selection</b> .....	<b>36</b>
<b>Appendix D – Effectiveness evidence</b> .....	<b>37</b>
<b>Appendix E – Forest plots</b> .....	<b>38</b>
<b>Appendix F – GRADE and/or GRADE-CERQual tables</b> .....	<b>39</b>
<b>Appendix G – Economic evidence study selection</b> .....	<b>40</b>
<b>Appendix H – Economic evidence tables</b> .....	<b>41</b>
<b>Appendix I – Health economic model</b> .....	<b>42</b>
<b>Appendix J – Excluded studies</b> .....	<b>43</b>
<b>Appendix K – Research recommendations – full details</b> .....	<b>59</b>

# 1 Identification of hypopituitarism (when to investigate)

## 1.1 Review question

When should people with head injury be investigated for hypopituitarism?

### 1.1.1 Introduction

Hypopituitarism is a clinical state due to absence of or reduction in hormones produced by the pituitary gland. The hormones produced by the anterior part of the pituitary are growth hormone, gonadotrophins (luteinizing hormone, follicle stimulating hormone or LH, FSH), Thyroid Stimulating Hormone (TSH), prolactin and adrenocorticotrophic hormone, ACTH) while the main hormone produced by the posterior part of the pituitary is arginine vasopressin (AVP); in hypopituitarism these hormones may be deficient in isolation or in combination. In infants and children, congenital hypopituitarism and septo-optic dysplasia are causes for early onset hypopituitarism. In older children and in adults, pituitary and hypothalamic tumours, traumatic brain injury and pituitary haemorrhage may cause hypopituitarism presenting in later life with varying severity.

Hypopituitarism may present acutely with cortisol deficiency and central diabetes insipidus, for instance with traumatic brain injury. Cortisol deficiency is characterized by tiredness, lethargy and inability to handle stress with potential escalation to adrenal crisis, a life-threatening state. Inability to produce AVP causing central diabetes insipidus may lead to dehydration and hypernatraemia, which may also be life threatening, if not treated promptly. For those with a more insidious onset, growth and puberty may be adversely affected in children and sexual dysfunction may occur in adults. A reduction in the production of TSH may lead to hypothyroidism with clinical features of tiredness, constipation and low mood in both children and adults.

Treatment of hypopituitarism is generally well accepted by patients and outcomes are satisfactory although monitoring and optimisation of therapy need to be undertaken through regular endocrine review in both children and adults. This review question looks at when people with head injury should be investigated for hypopituitarism.

### 1.1.2 Summary of the protocol

For full details see the review protocol in Appendix A.

**Table 1: PICO characteristics of review question**

<b>Population</b>	<p>Inclusion: Infants, children and adults with head injury who are being screened for hypopituitarism:</p> <ul style="list-style-type: none"><li>• Adults (aged <math>\geq 16</math> years)</li><li>• Children (aged <math>\geq 1</math> to <math>&lt; 16</math> years)</li><li>• Infants (aged <math>&lt; 1</math> year)</li></ul> <p>Mixed population studies will be included but downgraded for indirectness. Cut-off of 60% will be used for all age groups.</p> <p>Include all severities and stratify by GCS severity:</p> <ul style="list-style-type: none"><li>• Mild GCS 13-15</li><li>• Moderate 9-12</li><li>• Severe GCS 3-8</li></ul>
-------------------	--

	<p>Exclusion: Adults and children (including infants under 1 year) with superficial injuries to the eye or face without suspected or confirmed head or brain injury.</p>
<p><b>Intervention</b></p>	<p>Investigation for hypopituitarism in acute phase</p> <p>Strata:</p> <ol style="list-style-type: none"> <li>1. In ED</li> <li>2. Admission in hospital but not in ED</li> <li>3. After discharge, within 1 year of injury</li> </ol> <p><i>All timepoints are relevant for investigations for hypopituitarism</i></p> <p><i>Note from studies if the investigation was ad-hoc or if it was routine screening.</i></p> <p><i>Diagnostic testing for hypopituitarism:</i>  <i>Basal Pituitary investigations are typically similar at the time of presentation and 1 year later. These are generally: electrolytes, cortisol + ACTH, IGF-I, Prolactin, thyroid function. Depending on the circumstances, some centres might want to do a synacthen instead of random cortisol + ACTH.</i></p> <p><i>In children, there is a case to investigate growth failure. For this, a dynamic function test may be required at the 1 year mark.</i></p>
<p><b>Comparison</b></p>	<p>Investigation for hypopituitarism in chronic phase:</p> <ul style="list-style-type: none"> <li>• ≥1 year after injury</li> </ul>
<p><b>Outcomes</b></p>	<p>All outcomes are considered equally important for decision making and therefore have all been rated as critical:</p> <ul style="list-style-type: none"> <li>• Mortality</li> <li>• Quality of life (all validated quality of life scores).</li> <li>• Need for treatment of hypopituitarism (growth rate for children will be covered here)</li> <li>• Time to treatment of hypopituitarism</li> <li>• Return to work/return to school</li> </ul> <p>Same outcomes applicable to both adults and children.</p> <p>All-follow-up times will be considered.</p>
<p><b>Study design</b></p>	<p>Randomised controlled trials (RCTs), systematic reviews of RCTs.        If no RCT evidence is available, non-randomised studies will be considered if they adjust for key confounders, starting with prospective cohort studies.</p> <p>Key confounders:</p> <p><i>Adults:</i></p> <ul style="list-style-type: none"> <li>• Extent of extra cranial injury (other organ support)</li> </ul> <p><i>Children:</i></p> <ul style="list-style-type: none"> <li>• Extent of extra cranial injury (other organ support)</li> <li>• Age (in children- young child not in adults)</li> </ul> <p>Note from committee: If there are insufficient studies (quantity and/or quality) found that adjust for key confounders, studies that do not adjust for these confounders will be included.</p> <p>Studies will be downgraded for indirectness if not adjusted for key confounders.</p>

1 **1.1.3 Methods and process**

2 This evidence review was developed using the methods and process described in  
3 [Developing NICE guidelines: the manual](#). Methods specific to this review question are  
4 described in the review protocol in appendix A and the methods document.

5 Declarations of interest were recorded according to [NICE's conflicts of interest policy](#).

6

1 **1.1.4 Effectiveness evidence**

2 **1.1.4.1 Included studies**

3 Searches were performed for both randomised controlled trials and observational studies  
4 matching the protocol, as well as systematic reviews of these types of studies, which  
5 compared at least two different groups of people with differing time-points for investigation of  
6 hypopituitarism (acute vs. chronic). However, no relevant studies comparing relevant  
7 outcomes between two groups of people were identified. Various studies did compare the  
8 prevalence of hypopituitarism at different time-points in the same group of people, but these  
9 did not match the review protocol as repeated testing in the same group of people does not  
10 give insight into whether timing of testing affects clinical outcomes, such as mortality or  
11 quality of life specified in the protocol, which was the aim of this review protocol.

12 See also the study selection flow chart in Appendix C.

13 **1.1.4.2 Excluded studies**

14 See the excluded studies list in Appendix J.

15 **1.1.5 Summary of studies included in the effectiveness evidence**

16 No clinical evidence was identified for this review.

17 **1.1.6 Summary of the effectiveness evidence**

18 No clinical evidence was identified for this review.

19



1 **1.1.7 Economic evidence**

2 **1.1.7.1 Included studies**

3 No health economic studies were included.

4 **1.1.7.2 Excluded studies**

5 No relevant health economic studies were excluded due to assessment of limited  
6 applicability or methodological limitations.

7 See also the health economic study selection flow chart in Appendix G.

1 **1.1.8 Summary of included economic evidence**

2 None.

3 **1.1.9 Economic model**

4 Modelling was not conducted for this review.

1 **1.1.11 Evidence statements**

2 **Effectiveness/Qualitative**

- 3 • No clinical evidence was identified for this review.

4 **Economic**

- 5 • No relevant economic evaluations were identified.

6 **1.1.12 The committee's discussion and interpretation of the evidence**

7 **1.1.12.1. The outcomes that matter most**

8 The committee considered all outcomes as equally important for decision making and  
9 therefore have all been rated as critical: mortality, quality of life, need for treatment of  
10 hypopituitarism (including growth rate of children), time to treatment of hypopituitarism and  
11 return to work/return to school). All outcomes related to adults and children. All follow-up  
12 times were considered, as the committee acknowledged that studies with a long duration of  
13 follow-up can be difficult to conduct.

14 No studies suitable for this review were identified, as there were no studies comparing two  
15 different groups of people with differing time-points for investigation of hypopituitarism (acute  
16 vs. chronic). There were studies that compared the prevalence of hypopituitarism at different  
17 time points in the same group of people but this did not match the protocol.

18 **1.1.12.2 The quality of the evidence**

19 No clinical evidence was included in this review.

20 **1.1.12.3 Benefits and harms**

21 No evidence was included in this review. The committee acknowledged that hypopituitarism  
22 can be difficult to recognise early on which can lead to delay in diagnosis and treatment.  
23 They therefore thought it important to make a research recommendation to identify those  
24 who may have hypopituitarism. The committee based the research recommendation on the  
25 original review question to discover the best time to investigate those with head injury for  
26 hypopituitarism. This would include finding out the incidence of hypopituitarism in head injury.  
27 The committee thought that finding out the rates of hypopituitarism after head injury in  
28 different cohorts (intensive care, admitted to wards, people discharged) would be useful, and  
29 how it depends on the time it is measured in future research.

30 **1.1.12.4 Cost effectiveness and resource use**

31 No economic evaluations were found for this question. Given the lack of both clinical and  
32 economic evidence the committee decided to make a research recommendation.

33 **1.1.12.5 Other factors the committee took into account**

34 None.

35

# 1   **References**

2

- 3   1.   National Institute for Health and Care Excellence. Developing NICE guidelines: the  
4       manual [updated January 2022]. London. National Institute for Health and Care  
5       Excellence, 2014. Available from:  
6       <https://www.nice.org.uk/process/pmg20/chapter/introduction>

7

1 **Appendices**

2

3 **Appendix A – Review protocols**

4 **Review protocol for identification of hypopituitarism (when to investigate)**

ID	Field	Content
0.	PROSPERO registration number	[Complete this section with the PROSPERO registration number once allocated]
1.	Review title	<p>When should people with head injury be investigated for hypopituitarism?</p> <p>TBI may cause pituitary gland dysfunction contributing to significant morbidity and mortality from TBI.</p> <p>Inadequate secretion of one or more of the hormones secreted by the pituitary is known as hypopituitarism.</p> <p>Hormones secreted by pituitary gland:</p> <p>ACTCH (adrenocorticotrophic hormone): deficiency causes weakness, lethargy, weight loss. Findings: hypotension, hyponatremia, hypoglycaemia, hypercalcaemia, anaemia, fatigue</p> <p>Growth hormone: deficiency causes decreased energy, low mood, neuropsychiatric and cognitive symptoms. Finding: decreased lean body mass, increased fat mass, altered metabolic profile, decreased exercise capacity</p> <p><b>LH Luteinizing Hormone</b> /FSH Follicle stimulating hormone: deficiency in women, symptoms include irregular or stopped menstrual periods and infertility. In men, symptoms include loss of body and facial hair, weakness, lack of interest in sexual activity, erectile dysfunction, and infertility.</p>

		<p>TSH thyroid stimulating hormone (TSH) deficiency presents with fatigue, lethargy, cold intolerance, and weight gain.</p> <p>Vasopressin: deficiency causes polyuria, polydipsia, nocturia, incontinence</p> <p><u>Current practice when are they investigated?</u></p> <p>Not everyone gets investigated.</p> <p>People are investigated when they are symptomatic.</p>
2.	Review question	When should people with head injury be investigated for hypopituitarism?
3.	Objective	<p>To determine when should people with head injury be investigated for hypopituitarism.</p> <p>There is currently no guidance for the screening and detection of hypopituitarism patients with TBI, with significant variation in practice.</p> <p>Scope comments:          As hypopituitarism symptoms may not be immediate, importance of advising of follow up visit to GP with related head injury/pituitary symptoms, and recording this clearly on medical records.</p> <p>Discharge and follow up- may not be possible to identify hypopituitarism if discharge is within shorter time frame i.e few days/weeks. Hypopituitarism symptoms may not manifest immediately.</p>
4.	Searches	<p>The following databases (from inception) will be searched:</p> <ul style="list-style-type: none"> <li>• Cochrane Central Register of Controlled Trials (CENTRAL)</li> <li>• Cochrane Database of Systematic Reviews (CDSR)</li> <li>• Embase</li> </ul>

		<ul style="list-style-type: none"> <li>• MEDLINE</li> <li>• Epistemonikos</li> </ul> <p>Searches will be restricted by:</p> <ul style="list-style-type: none"> <li>• English language studies</li> <li>• Human studies</li> </ul> <p>Other searches:</p> <ul style="list-style-type: none"> <li>• [Inclusion lists of systematic reviews]</li> </ul> <p>The searches may be re-run 6 weeks before the final committee meeting and further studies retrieved for inclusion if relevant.</p> <p>The full search strategies will be published in the final review.</p> <p>Medline search strategy to be quality assured using the PRESS evidence-based checklist (see methods chapter for full details).</p>
5.	Condition or domain being studied	Hypopituitarism after head injury
6.	Population	<p>i) Inclusion: Infants, children and adults with head injury who are being screened for hypopituitarism</p> <ul style="list-style-type: none"> <li>• Adults (aged ≥16 years)</li> <li>• Children (aged ≥1 to &lt;16 years)</li> </ul>

		<ul style="list-style-type: none"> <li>• Infants (aged &lt;1 year)</li> </ul> <p>Mixed population studies will be included but downgraded for indirectness. Cut-off of 60% will be used for all age groups.</p> <p>Include all severities</p> <p>Strata: severity of TBI based on GCS</p> <ul style="list-style-type: none"> <li>• Mild GCS 13-15</li> <li>• Moderate 9-12</li> <li>• Severe GCS 3-8</li> </ul> <p>Exclusion:</p> <p>Adults and children (including infants under 1 year) with superficial injuries to the eye or face without suspected or confirmed head or brain injury.</p>
7.	Intervention	<p>Investigation for hypopituitarism in acute phase</p> <p>Strata:</p> <ol style="list-style-type: none"> <li>1. In ED</li> <li>2. Admission in hospital but not in ED</li> <li>3. After discharge, within 1 year of injury</li> </ol> <p>All timepoints are relevant for investigations for hypopituitarism</p> <p>Note from studies if the investigation was adhoc or if it was routine screening.</p> <p>Diagnostic testing for hypopituitarism:</p>



		<p>Basal Pituitary investigations are typically similar at the time of presentation and 1 year later. These are generally: electrolytes, cortisol + ACTH, IGF-I, Prolactin, thyroid function. Depending on the circumstances, some centres might want to do a synacthen instead of random cortisol + ACTH.</p> <p>In children, there is a case to investigate growth failure. For this, a dynamic function test may be required at the 1 year mark.</p>
8.	Comparator	<p>Investigation for hypopituitarism in chronic phase</p> <ul style="list-style-type: none"> <li>➤ ≥1 year after injury</li> </ul>
9.	Types of study to be included	<p>Randomised controlled trials (RCTs), systematic reviews of RCTs. If no RCT evidence is available, non-randomised studies will be considered if they adjust for key confounders, starting with prospective cohort studies.</p> <p>Key confounders:</p> <p>Adults:</p> <ul style="list-style-type: none"> <li>• Extent of extra cranial injury (other organ support)</li> </ul> <p>Children:</p> <ul style="list-style-type: none"> <li>• Extent of extra cranial injury (other organ support)</li> <li>• Age (in children- young child not in adults)</li> </ul> <p>Note from committee: If there are insufficient studies (quantity and/or quality) found that adjust for key confounders, studies that do not adjust for these confounders will be included.</p> <p>Studies will be downgraded for indirectness if not adjusted for key confounders.</p>
10.	Other exclusion criteria	Non-English language studies.

		<p>Conference abstracts will be excluded as it is expected there will be sufficient full text published studies available.</p> <p>Studies not adjusted for pre-specified key confounders</p>
11.	Context	<p>There is currently no guidance for the screening and detection of hypopituitarism patients with TBI, with significant variation in practice.</p>
12.	Primary outcomes (critical outcomes)	<p>All outcomes are considered equally important for decision making and therefore have all been rated as critical:</p> <ul style="list-style-type: none"> <li>• Mortality</li> <li>• Quality of life(all validated quality of life scores).</li> <li>• Need for treatment of hypopituitarism (growth rate for children will be covered here)</li> <li>• Time to treatment of hypopituitarism</li> <li>• Return to work/return to school</li> </ul> <p>Same outcomes applicable to both adults and children.</p> <p>All-follow-up times will be considered.</p>
13.	Data extraction (selection and coding)	<p>10% of the abstracts will be reviewed by two reviewers, with any disagreements resolved by discussion or, if necessary, a third independent reviewer.</p> <p>The full text of potentially eligible studies will be retrieved and will be assessed in line with the criteria outlined above.</p>

		<p>A standardised form will be used to extract data from studies (see <a href="#">Developing NICE guidelines: the manual</a> section 6.4).</p> <p>10% of all evidence reviews are quality assured by a senior research fellow. This includes checking:</p> <ul style="list-style-type: none"> <li>• papers were included /excluded appropriately</li> <li>• a sample of the data extractions</li> <li>• correct methods are used to synthesise data</li> <li>• a sample of the risk of bias assessments</li> </ul> <p>Disagreements between the review authors over the risk of bias in particular studies will be resolved by discussion, with involvement of a third review author where necessary.</p>
14.	Risk of bias (quality) assessment	<p>Risk of bias will be assessed using the appropriate checklist as described in <a href="#">Developing NICE guidelines: the manual</a>.</p> <p>For Intervention reviews</p> <ul style="list-style-type: none"> <li>• Systematic reviews: Risk of Bias in Systematic Reviews (ROBIS)</li> <li>• Randomised Controlled Trial: Cochrane RoB (2.0)</li> <li>• Non randomised study, including cohort studies: Cochrane ROBINS-I</li> </ul>
15.	Strategy for data synthesis	<ul style="list-style-type: none"> <li>• Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5). Fixed-effects (Mantel-Haenszel) techniques will be used to calculate risk ratios for the binary outcomes where possible. Continuous outcomes will be analysed using an inverse variance method for pooling weighted mean differences.</li> </ul>

		<p>Heterogeneity between the studies in effect measures will be assessed using the <math>I^2</math> statistic and visually inspected. An <math>I^2</math> value greater than 50% will be considered indicative of substantial heterogeneity. Sensitivity analyses will be conducted based on pre-specified subgroups using stratified meta-analysis to explore the heterogeneity in effect estimates. If this does not explain the heterogeneity, the results will be presented pooled using random-effects.</p> <ul style="list-style-type: none"> <li>• GRADEpro will be used to assess the quality of evidence for each outcome, taking into account individual study quality and the meta-analysis results. The 4 main quality elements (risk of bias, indirectness, inconsistency and imprecision) will be appraised for each outcome.</li> </ul> <p>The risk of bias across all available evidence will be evaluated for each outcome using an adaptation of the 'Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox' developed by the international GRADE working group <a href="http://www.gradeworkinggroup.org/">http://www.gradeworkinggroup.org/</a></p> <ul style="list-style-type: none"> <li>• Where meta-analysis is not possible, data will be presented and quality assessed individually per outcome.</li> </ul>	
16.	Analysis of sub-groups	<p>Subgroups that will be investigated if heterogeneity is present: None identified</p>	
17.	Type and method of review	<input checked="" type="checkbox"/>	Intervention
		<input type="checkbox"/>	Diagnostic
		<input type="checkbox"/>	Prognostic
		<input type="checkbox"/>	Qualitative

		<input type="checkbox"/>	Epidemiologic	
		<input type="checkbox"/>	Service Delivery	
		<input type="checkbox"/>	Other (please specify)	
18.	Language	English		
19.	Country	England		
20.	Anticipated or actual start date	<p>[For the purposes of PROSPERO, the date of commencement for the systematic review can be defined as any point after completion of a protocol but before formal screening of the identified studies against the eligibility criteria begins.</p> <p>A protocol can be deemed complete after sign-off by the NICE team with responsibility for quality assurance.]</p>		
21.	Anticipated completion date	<p>[Give the date by which the guideline is expected to be published. This field may be edited at any time. All edits will appear in the record audit trail. A brief explanation of the reason for changes should be given in the Revision Notes facility.]</p>		
22.	Stage of review at time of this submission	Review stage	Started	Completed
		Preliminary searches	<input checked="" type="checkbox"/>	<input type="checkbox"/>
		Piloting of the study selection process	<input type="checkbox"/>	<input type="checkbox"/>
		Formal screening of search results against eligibility criteria	<input type="checkbox"/>	<input type="checkbox"/>
		Data extraction	<input type="checkbox"/>	<input type="checkbox"/>
		Risk of bias (quality) assessment	<input type="checkbox"/>	<input type="checkbox"/>

		Data analysis	<input type="checkbox"/>	<input type="checkbox"/>
23.	Named contact	<p>5a. Named contact National Guideline Centre</p> <p>5b Named contact e-mail [Guideline email]@nice.org.uk [Developer to check with Guideline Coordinator for email address]</p> <p>5e Organisational affiliation of the review National Institute for Health and Care Excellence (NICE) and [National Guideline Alliance / National Guideline Centre / NICE Guideline Updates Team / NICE Public Health Guideline Development Team] [Note it is essential to use the template text here and one of the centre options to enable PROSPERO to recognise this as a NICE protocol]</p>		
24.	Review team members	<p>[Give the title, first name, last name and the organisational affiliations of each member of the review team. Affiliation refers to groups or organisations to which review team members belong.]</p> <p>From the National Guideline Centre: [Guideline lead] [Senior systematic reviewer] Systematic reviewer [Health economist] [Information specialist] [Others]</p>		

25.	Funding sources/sponsor	This systematic review is being completed by the National Guideline Centre which receives funding from NICE.
26.	Conflicts of interest	All guideline committee members and anyone who has direct input into NICE guidelines (including the evidence review team and expert witnesses) must declare any potential conflicts of interest in line with NICE's code of practice for declaring and dealing with conflicts of interest. Any relevant interests, or changes to interests, will also be declared publicly at the start of each guideline committee meeting. Before each meeting, any potential conflicts of interest will be considered by the guideline committee Chair and a senior member of the development team. Any decisions to exclude a person from all or part of a meeting will be documented. Any changes to a member's declaration of interests will be recorded in the minutes of the meeting. Declarations of interests will be published with the final guideline.
27.	Collaborators	Development of this systematic review will be overseen by an advisory committee who will use the review to inform the development of evidence-based recommendations in line with section 3 of <a href="#">Developing NICE guidelines: the manual</a> . Members of the guideline committee are available on the NICE website: <a href="#">[NICE guideline webpage]</a> .
28.	Other registration details	<a href="#">[Give the name of any organisation where the systematic review title or protocol is registered (such as with The Campbell Collaboration, or The Joanna Briggs Institute) together with any unique identification number assigned. If extracted data will be stored and made available through a repository such as the Systematic Review Data Repository (SRDR), details and a link should be included here. If none, leave blank.]</a>
29.	Reference/URL for published protocol	<a href="#">[Give the citation and link for the published protocol, if there is one.]</a>
30.	Dissemination plans	NICE may use a range of different methods to raise awareness of the guideline. These include standard approaches such as: <ul style="list-style-type: none"> <li>• notifying registered stakeholders of publication</li> <li>• publicising the guideline through NICE's newsletter and alerts</li> </ul>

		<ul style="list-style-type: none"> <li>• issuing a press release or briefing as appropriate, posting news articles on the NICE website, using social media channels, and publicising the guideline within NICE.</li> </ul> <p>[Add in any additional agree dissemination plans.]</p>	
31.	Keywords	Post-concussion syndrome, follow-up, discharge	
32.	Details of existing review of same topic by same authors	NA	
33.	Current review status	<input checked="" type="checkbox"/>	Ongoing
		<input type="checkbox"/>	Completed but not published
		<input type="checkbox"/>	Completed and published
		<input type="checkbox"/>	Completed, published and being updated
		<input type="checkbox"/>	Discontinued
34.	Additional information	[Provide any other information the review team feel is relevant to the registration of the review.]	
35.	Details of final publication	<a href="http://www.nice.org.uk">www.nice.org.uk</a>	

1

2



1 **Health economic review protocol**

<b>Review question</b>	<b>All questions – health economic evidence</b>
<b>Objectives</b>	To identify health economic studies relevant to any of the review questions.
<b>Search criteria</b>	<ul style="list-style-type: none"> <li>• Populations, interventions and comparators must be as specified in the clinical review protocol above.</li> <li>• Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis).</li> <li>• Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.)</li> <li>• Unpublished reports will not be considered unless submitted as part of a call for evidence.</li> <li>• Studies must be in English.</li> </ul>
<b>Search strategy</b>	A health economic study search will be undertaken using population-specific terms and a health economic study filter – see appendix B below. The search covered all years
<b>Review strategy</b>	<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2006, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.</p> <p>Studies published in 2006 or later that were included in the previous guidelines will be reassessed for inclusion and may be included or selectively excluded based on their relevance to the questions covered in this update and whether more applicable evidence is also identified.</p> <p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).<sup>1</sup></p> <p><b>Inclusion and exclusion criteria</b></p> <ul style="list-style-type: none"> <li>• If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’ then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile.</li> <li>• If a study is rated as either ‘Not applicable’ or with ‘Very serious limitations’ then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile.</li> <li>• If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or both then there is discretion over whether it should be included.</li> </ul>

**Where there is discretion**

The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.

The health economist will be guided by the following hierarchies.

*Setting:*

- UK NHS (most applicable).
- OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).
- OECD countries with predominantly private health insurance systems (for example, Switzerland).
- Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.

*Health economic study type:*

- Cost–utility analysis (most applicable).
- Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.

*Year of analysis:*

- The more recent the study, the more applicable it will be.
- Studies published in 2006 or later (including any such studies included in the previous guidelines) but that depend on unit costs and resource data entirely or predominantly from before 2006 will be rated as ‘Not applicable’.
- Studies published before 2006 (including any such studies included in the previous guidelines) will be excluded before being assessed for applicability and methodological limitations.

*Quality and relevance of effectiveness data used in the health economic analysis:*

- The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.



## 1 Appendix B – Literature search strategies

2 The literature searches for this review are detailed below and complied with the methodology  
3 outlined in Developing NICE guidelines: the manual.<sup>1</sup>

4 For more information, please see the Methodology review published as part of the  
5 accompanying documents for this guideline.

### B.1 Clinical search literature search strategy

7 Searches were constructed using a Head Injury population and terms for Hypopituitarism. No  
8 filters were applied to cover both the intervention and diagnostic elements of the review.

9 **Table 2: Database parameters, filters and limits applied**

Database	Dates searched	Search filter used
Medline (OVID)	1946 – 22 June 2022	Exclusions (animal studies, letters, comments, editorials, case studies/reports)  English language
Embase (OVID)	1974 – 22 June 2022	Exclusions (animal studies, letters, comments, editorials, case studies/reports, conference abstracts)  English language
The Cochrane Library (Wiley)	Cochrane Reviews to 2022 Issue 6 of 12 CENTRAL to 2022 Issue 6 of 12	
Epistemonikos (The Epistemonikos Foundation)	Inception to 22 June 2022	Exclusions (Cochrane reviews)

#### 10 Medline (Ovid) search terms

1.	craniocerebral trauma/ or exp brain injuries/ or coma, post-head injury/ or exp head injuries, closed/ or head injuries, penetrating/ or exp intracranial hemorrhage, traumatic/ or exp skull fractures/
2.	((skull or cranial) adj3 fracture*).ti,ab.
3.	((head or brain or craniocerebral or cranial or cerebral or skull) adj4 (injur* or trauma*).ti,ab.
4.	(trauma* and ((subdural or intracranial) adj2 (h?ematoma* or h?emorrhage* or bleed*))).ti,ab.
5.	or/1-4
6.	letter/
7.	editorial/
8.	news/
9.	exp historical article/
10.	Anecdotes as Topic/
11.	comment/
12.	case report/

13.	(letter or comment*).ti.
14.	or/6-13
15.	randomized controlled trial/ or random*.ti,ab.
16.	14 not 15
17.	animals/ not humans/
18.	exp Animals, Laboratory/
19.	exp Animal Experimentation/
20.	exp Models, Animal/
21.	exp Rodentia/
22.	(rat or rats or mouse or mice or rodent*).ti.
23.	or/16-22
24.	5 not 23
25.	limit 24 to English language
26.	Hypopituitarism/
27.	(Hypopituitarism* or hypopituitaryism* or PTHP).ti,ab.
28.	(pituitary adj2 (insufficien* or dysfunction* or injur* or damage* or function* or fail* or deficien* or hypofunction*)).ti,ab.
29.	(hypophysis adj2 (insufficien* or dysfunction* or injur* or damage* or function* or fail* or deficien* or hypofunction*)).ti,ab.
30.	Simmond* disease.ti,ab.
31.	or/26-30
32.	25 and 31

11 **Embase (Ovid) search terms**

1.	head injury/
2.	exp brain injury/
3.	skull injury/ or exp skull fracture/
4.	((head or brain or craniocerebral or cranial or cerebral or skull) adj4 (injur* or trauma*)).ti,ab.
5.	((skull or cranial) adj3 fracture*).ti,ab.
6.	(trauma* and ((subdural or intracranial) adj2 (h?ematoma* or h?emorrhage* or bleed*))).ti,ab.
7.	or/1-6
8.	letter.pt. or letter/
9.	note.pt.
10.	editorial.pt.
11.	(conference abstract or conference paper).pt.
12.	case report/ or case study/
13.	(letter or comment*).ti.
14.	or/8-13
15.	randomized controlled trial/ or random*.ti,ab.
16.	14 not 15
17.	animal/ not human/
18.	nonhuman/
19.	exp Animal Experiment/
20.	exp Experimental Animal/
21.	animal model/

22.	exp Rodent/
23.	(rat or rats or mouse or mice or rodent*).ti.
24.	or/16-23
25.	7 not 24
26.	limit 25 to English language
27.	hypopituitarism/
28.	(Hypopituitarism* or hypopituitaryism* or PTHP).ti,ab.
29.	(pituitary adj2 (insufficien* or dysfunction* or injur* or damage* or function* or fail* or deficien* or hypofunction*)).ti,ab.
30.	(hypophysis adj2 (insufficien* or dysfunction* or injur* or damage* or function* or fail* or deficien* or hypofunction*)).ti,ab.
31.	Simmond* disease.ti,ab.
32.	or/27-30
33.	26 and 32

## 12 Cochrane Library (Wiley) search terms

#1.	MeSH descriptor: [Craniocerebral Trauma] this term only
#2.	MeSH descriptor: [Brain Injuries] explode all trees
#3.	MeSH descriptor: [Coma, Post-Head Injury] this term only
#4.	MeSH descriptor: [Head Injuries, Closed] explode all trees
#5.	MeSH descriptor: [Head Injuries, Penetrating] this term only
#6.	MeSH descriptor: [Intracranial Hemorrhage, Traumatic] explode all trees
#7.	MeSH descriptor: [Skull Fractures] explode all trees
#8.	((skull or cranial) near/3 fracture*):ti,ab
#9.	((head or brain or craniocerebral or intracranial or cranial or skull) near/3 (injur* or trauma*)):ti,ab
#10.	(trauma* and ((subdural or intracranial) near/2 (h?ematoma* or h?emorrhage* or bleed*)):ti,ab
#11.	#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
#12.	MeSH descriptor: [Hypopituitarism] this term only
#13.	(Hypopituitarism* or hypopituitaryism* or PTHP):ti,ab
#14.	(pituitary near/2 (insufficien* or dysfunction* or injur* or damage* or function* or fail* or deficien* or hypofunction*)):ti,ab
#15.	Simmond* disease:ti,ab
#16.	#12 or #13 or #14 or #15
#17.	#11 and #16

## 13 Epistemonikos search terms

1.	(title:(Hypopituitarism* OR hypopituitaryism* OR PTHP)) OR abstract:(Hypopituitarism* OR hypopituitaryism* OR PTHP)) OR (title:(pituitary AND (insufficien* OR dysfunction* OR injur* OR damage* OR function* OR fail* OR deficien* OR hypofunction*)) OR abstract:(pituitary AND (insufficien* OR dysfunction* OR injur* OR damage* OR function* OR fail* OR deficien* OR hypofunction*))) OR (title:(hypophysis AND (insufficien* OR dysfunction* OR injur* OR damage* OR function* OR fail* OR deficien* OR hypofunction*)) OR abstract:(hypophysis AND (insufficien* OR dysfunction* OR injur* OR damage* OR function* OR fail* OR deficien* OR hypofunction*))) OR (title:(Simmond* disease) OR abstract:(Simmond* disease))
----	---

## B1.2 Health Economics literature search strategy

15 Health economic evidence was identified by conducting searches using terms for a broad  
16 Head Injury population. The following databases were searched: NHS Economic Evaluation  
17 Database (NHS EED - this ceased to be updated after 31<sup>st</sup> March 2015), Health Technology  
18 Assessment database (HTA - this ceased to be updated from 31<sup>st</sup> March 2018) and The  
19 International Network of Agencies for Health Technology Assessment (INAHTA). Searches  
20 for recent evidence were run on Medline and Embase from 2014 onwards for health  
21 economics, and all years for quality-of-life studies.

22 **Table 3: Database parameters, filters and limits applied**

Database	Dates searched	Search filters and limits applied
Medline (OVID)	Health Economics 1 January 2014 – 22 June 2022	Health economics studies Quality of life studies
	Quality of Life 1946 – 22 June 2022	Exclusions (animal studies, letters, comments, editorials, case studies/reports)  English language
Embase (OVID)	Health Economics 1 January 2014 – 22 June 2022	Health economics studies Quality of life studies
	Quality of Life 1974 – 22 June 2022	Exclusions (animal studies, letters, comments, editorials, case studies/reports, conference abstracts)  English language
NHS Economic Evaluation Database (NHS EED) (Centre for Research and Dissemination - CRD)	Inception – 31 <sup>st</sup> March 2015	
Health Technology Assessment Database (HTA) (Centre for Research and Dissemination – CRD)	Inception – 31 <sup>st</sup> March 2018	
The International Network of Agencies for Health Technology Assessment (INAHTA)	Inception – 22 June 2022	English language

### 23 Medline (Ovid) search terms

1.	craniocerebral trauma/ or exp brain injuries/ or coma, post-head injury/ or exp head injuries, closed/ or head injuries, penetrating/ or exp intracranial hemorrhage, traumatic/ or exp skull fractures/
2.	((skull or cranial) adj3 fracture*).ti,ab.
3.	((head or brain or craniocerebral or intracranial or cranial or skull) adj3 (injur* or trauma*)),ti,ab.
4.	(trauma* and ((subdural or intracranial or brain) adj2 (h?ematoma* or h?emorrhage* or bleed*))).ti,ab.

5.	or/1-4
6.	letter/
7.	editorial/
8.	news/
9.	exp historical article/
10.	Anecdotes as Topic/
11.	comment/
12.	case report/
13.	(letter or comment*).ti.
14.	or/6-13
15.	randomized controlled trial/ or random*.ti,ab.
16.	14 not 15
17.	animals/ not humans/
18.	exp Animals, Laboratory/
19.	exp Animal Experimentation/
20.	exp Models, Animal/
21.	exp Rodentia/
22.	(rat or rats or mouse or mice or rodent*).ti.
23.	or/16-22
24.	5 not 23
25.	limit 24 to English language
26.	economics/
27.	value of life/
28.	exp "costs and cost analysis"/
29.	exp Economics, Hospital/
30.	exp Economics, medical/
31.	Economics, nursing/
32.	economics, pharmaceutical/
33.	exp "Fees and Charges"/
34.	exp budgets/
35.	budget*.ti,ab.
36.	cost*.ti.
37.	(economic* or pharmaco?economic*).ti.
38.	(price* or pricing*).ti,ab.
39.	(cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
40.	(financ* or fee or fees).ti,ab.
41.	(value adj2 (money or monetary)).ti,ab.
42.	or/26-41
43.	quality-adjusted life years/
44.	sickness impact profile/



45.	(quality adj2 (wellbeing or well being)).ti,ab.
46.	sickness impact profile.ti,ab.
47.	disability adjusted life.ti,ab.
48.	(qal* or qtime* or qwb* or daly*).ti,ab.
49.	(euroqol* or eq5d* or eq 5*).ti,ab.
50.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
51.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
52.	(hui or hui1 or hui2 or hui3).ti,ab.
53.	(health* year* equivalent* or hye or hyes).ti,ab.
54.	discrete choice*.ti,ab.
55.	rosser.ti,ab.
56.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
57.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
58.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
59.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
60.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
61.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
62.	or/43-61
63.	25 and (42 or 62)

24 **Embase (Ovid) search terms**

1.	head injury/
2.	exp brain injury/
3.	skull injury/ or exp skull fracture/
4.	((head or brain or craniocerebral or intracranial or cranial or skull) adj3 (injur* or trauma*).ti,ab.
5.	((skull or cranial) adj3 fracture*).ti,ab.
6.	(trauma* and ((subdural or intracranial or brain) adj2 (h?ematoma* or h?emorrhage* or bleed*))).ti,ab.
7.	or/1-6
8.	letter.pt. or letter/
9.	note.pt.
10.	editorial.pt.
11.	(conference abstract or conference paper).pt.
12.	case report/ or case study/
13.	(letter or comment*).ti.
14.	or/8-13
15.	randomized controlled trial/ or random*.ti,ab.
16.	14 not 15
17.	animal/ not human/
18.	nonhuman/
19.	exp Animal Experiment/
20.	exp Experimental Animal/

21.	animal model/
22.	exp Rodent/
23.	(rat or rats or mouse or mice or rodent*).ti.
24.	or/16-23
25.	7 not 24
26.	limit 25 to English language
27.	health economics/
28.	exp economic evaluation/
29.	exp health care cost/
30.	exp fee/
31.	budget/
32.	funding/
33.	budget*.ti,ab.
34.	cost*.ti.
35.	(economic* or pharmaco?economic*).ti.
36.	(price* or pricing*).ti,ab.
37.	(cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
38.	(financ* or fee or fees).ti,ab.
39.	(value adj2 (money or monetary)).ti,ab.
40.	or/27-39
41.	quality-adjusted life years/
42.	"quality of life index"/
43.	short form 12/ or short form 20/ or short form 36/ or short form 8/
44.	sickness impact profile/
45.	(quality adj2 (wellbeing or well being)).ti,ab.
46.	sickness impact profile.ti,ab.
47.	disability adjusted life.ti,ab.
48.	(qal* or qtime* or qwb* or daly*).ti,ab.
49.	(euroqol* or eq5d* or eq 5*).ti,ab.
50.	(qol* or hq1* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
51.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
52.	(hui or hui1 or hui2 or hui3).ti,ab.
53.	(health* year* equivalent* or hye or hyes).ti,ab.
54.	discrete choice*.ti,ab.
55.	rosser.ti,ab.
56.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
57.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
58.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
59.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
60.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
61.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
62.	or/41-61

63.	26 and (40 or 62)
-----	-------------------

25 **NHS EED and HTA (CRD) search terms**

#1.	MeSH DESCRIPTOR Brain Injuries EXPLODE ALL TREES
#2.	MeSH DESCRIPTOR Craniocerebral Trauma
#3.	MeSH DESCRIPTOR Coma, Post-Head Injury
#4.	MeSH DESCRIPTOR Head Injuries, Closed EXPLODE ALL TREES
#5.	MeSH DESCRIPTOR Head Injuries, Penetrating
#6.	MeSH DESCRIPTOR Intracranial Hemorrhage, Traumatic EXPLODE ALL TREES
#7.	MeSH DESCRIPTOR Skull Fractures EXPLODE ALL TREES
#8.	(((skull or cranial) adj3 fracture*))
#9.	(((head or brain or craniocerebral or intracranial or cranial or skull) adj3 (injur* or trauma**)))
#10.	(((trauma* and ((subdural or intracranial or brain) adj2 (h?ematoma* or h?emorrhage* or bleed*))))
#11.	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10


26 **INAHTA search terms**

1.	(((trauma* and ((subdural or intracranial or brain) and (haematoma* or hematoma* or haemorrhage* or hemorrhage* or bleed*))))[Title] AND (((trauma* and ((subdural or intracranial or brain) and (haematoma* or hematoma* or haemorrhage* or hemorrhage* or bleed*))))[Title]) OR (((skull or cranial) and fracture*)[Title] OR (((skull or cranial) and fracture*)[abs]) OR (((head or brain or craniocerebral or intracranial or cranial or skull) and (injur* or trauma**))[Title] OR (((head or brain or craniocerebral or intracranial or cranial or skull) and (injur* or trauma**))[abs]) OR ("Skull Fractures"[mhe] OR ("Intracranial Hemorrhage, Traumatic"[mhe] OR ("Head Injuries, Penetrating"[mh] OR ("Head Injuries, Closed"[mhe] OR ("Coma, Post-Head Injury"[mh] OR ("Brain Injuries"[mhe] OR ("Craniocerebral Trauma"[mh])
----	---

27

28 **Appendix C – Effectiveness evidence study selection**

29 Figure 1: Flow chart of clinical study selection for the review of investigation of  
30 hypopituitarism (when to investigate)



31  
32  
33

## **Appendix D – Effectiveness evidence**

No clinical evidence was identified for this review.

## **Appendix E – Forest plots**


No clinical evidence was identified for this review.

1 **Appendix F – GRADE and/or GRADE-CERQual tables**

2 No clinical evidence was identified for this review.

3

#### 4 Appendix G – Economic evidence study selection



\* Non-relevant population, intervention, comparison, design or setting; non-English language

5



- 1 **Appendix H – Economic evidence tables**
- 2 None.

1 **Appendix I – Health economic model**

2 Modelling was not undertaken for this review.

3

## 4 Appendix J – Excluded studies

### 5 Clinical studies

6 **Table 3: Studies excluded from the clinical review**

Study	Code [Reason]
Agha, A., Rogers, B., Mylotte, D. et al. (2004) Neuroendocrine dysfunction in the acute phase of traumatic brain injury. <i>Clinical Endocrinology</i> 60(5): 584-91	- No comparison between two separate groups of people tested in acute vs. chronic phase
Agha, A., Rogers, B., Sherlock, M. et al. (2004) Anterior pituitary dysfunction in survivors of traumatic brain injury. <i>Journal of Clinical Endocrinology &amp; Metabolism</i> 89(10): 4929-36	- No comparison between two separate groups of people tested in acute vs. chronic phase
Agha, A., Sherlock, M., Phillips, J. et al. (2005) The natural history of post-traumatic neurohypophysial dysfunction. <i>European Journal of Endocrinology</i> 152(3): 371-7	- No comparison between two separate groups of people tested in acute vs. chronic phase
Agha, A., Thornton, E., O'Kelly, P. et al. (2004) Posterior pituitary dysfunction after traumatic brain injury. <i>Journal of Clinical Endocrinology &amp; Metabolism</i> 89(12): 5987-92	- No comparison between two separate groups of people tested in acute vs. chronic phase
Agrawal, M.; Varshney, T.; Sinha, V. D. (2017) Prognostic Assessment of Endocrine Disturbances in Posttraumatic Subarachnoid Hemorrhage. <i>Indian Journal of Neurotrauma</i> 14(2-3): 109-115	- No comparison between two separate groups of people tested in acute vs. chronic phase
Aimaretti, G., Ambrosio, M. R., Di Somma, C. et al. (2004) Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury. <i>Clinical Endocrinology</i> 61(3): 320-6	- No comparison between two separate groups of people tested in acute vs. chronic phase
Aimaretti, G., Ambrosio, M. R., Di Somma, C. et al. (2005) Hypopituitarism induced by traumatic brain injury in the transition phase. <i>Journal of Endocrinological Investigation</i> 28(11): 984-9	- No comparison between two separate groups of people tested in acute vs. chronic phase
Aimaretti, G., Ambrosio, M. R., Di Somma, C. et al. (2005) Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study. <i>Journal of Clinical Endocrinology &amp; Metabolism</i> 90(11): 6085-92	- No comparison between two separate groups of people tested in acute vs. chronic phase

Study	Code [Reason]
Auble, B. A., Bollepalli, S., Makoroff, K. et al. (2014) Hypopituitarism in pediatric survivors of inflicted traumatic brain injury. <i>Journal of Neurotrauma</i> 31(4): 321-6	- No comparison between two separate groups of people tested in acute vs. chronic phase
Aylanc, H.; Tutunculer, F.; Sut, N. (2016) Evaluation of pituitary function in cases with the diagnosis of pediatric mild traumatic brain injury: Cross-sectional study. <i>Journal of Neurosciences in Rural Practice</i> 7(4): 537-543	- No comparison between two separate groups of people tested in acute vs. chronic phase
Bavisetty, S., Bavisetty, S., McArthur, D. L. et al. (2008) Chronic hypopituitarism after traumatic brain injury: risk assessment and relationship to outcome. <i>Neurosurgery</i> 62(5): 1080-93; discussion 1093	- No comparison between two separate groups of people tested in acute vs. chronic phase
Baxter, D., Sharp, D. J., Feeney, C. et al. (2013) Pituitary dysfunction after blast traumatic brain injury: The UK BIOSAP study. <i>Annals of Neurology</i> 74(4): 527-36	- No comparison between two separate groups of people tested in acute vs. chronic phase
Bellone, S., Einaudi, S., Caputo, M. et al. (2013) Measurement of height velocity is an useful marker for monitoring pituitary function in patients who had traumatic brain injury. <i>Pituitary</i> 16(4): 499-506	- No comparison between two separate groups of people tested in acute vs. chronic phase
Berg, C., Oeffner, A., Schumm-Draeger, P. M. et al. (2010) Prevalence of anterior pituitary dysfunction in patients following traumatic brain injury in a German multi-centre screening program. <i>Experimental &amp; Clinical Endocrinology &amp; Diabetes</i> 118(2): 139-44	- No comparison between two separate groups of people tested in acute vs. chronic phase
Bondanelli, M., De Marinis, L., Ambrosio, M. R. et al. (2004) Occurrence of pituitary dysfunction following traumatic brain injury. <i>Journal of Neurotrauma</i> 21(6): 685-96	- No comparison between two separate groups of people tested in acute vs. chronic phase
Briet, C., Braun, K., Lefranc, M. et al. (2019) Should We Assess Pituitary Function in Children After a Mild Traumatic Brain Injury? A Prospective Study. <i>Frontiers in Endocrinology</i> 10: 149	- No comparison between two separate groups of people tested in acute vs. chronic phase
Capatina, C., Capatina, C. O., Chirica, V. I. et al. (2016) Endocrine consequences of traumatic brain injury. Literature review. <i>Romanian Journal of Legal Medicine</i> 24(3): 199-203	- Review article but not a systematic review

Study	Code [Reason]
Casano-Sancho, P., Suarez, L., Ibanez, L. et al. (2013) Pituitary dysfunction after traumatic brain injury in children: is there a need for ongoing endocrine assessment?. <i>Clinical Endocrinology</i> 79(6): 853-8	- No comparison between two separate groups of people tested in acute vs. chronic phase
Castro, A. I., Lage, M., Peino, R. et al. (2007) A single growth hormone determination 30 minutes after the administration of the GHRH plus GHRP-6 test is sufficient for the diagnosis of somatotrope dysfunction in patients who have suffered traumatic brain injury. <i>Journal of Endocrinological Investigation</i> 30(3): 224-9	- No comparison between two separate groups of people tested in acute vs. chronic phase
Cuesta, M., Hannon, M. J., Crowley, R. K. et al. (2016) Symptoms of gonadal dysfunction are more predictive of hypopituitarism than nonspecific symptoms in screening for pituitary dysfunction following moderate or severe traumatic brain injury. <i>Clinical Endocrinology</i> 84(1): 92-8	- No comparison between two separate groups of people tested in acute vs. chronic phase
Dalwadi, P. P., Bhagwat, N. M., Tayde, P. S. et al. (2017) Pituitary dysfunction in traumatic brain injury: Is evaluation in the acute phase worthwhile?. <i>Indian Journal of Endocrinology and Metabolism</i> 21(1): 80-84	- No comparison between two separate groups of people tested in acute vs. chronic phase
Dassa, Y., Crosnier, H., Chevignard, M. et al. (2019) Pituitary deficiency and precocious puberty after childhood severe traumatic brain injury: a long-term follow-up prospective study. <i>European Journal of Endocrinology</i> 180(5): 281-290	- No comparison between two separate groups of people tested in acute vs. chronic phase
Dhume, C. Y. and Demelo, M. (2012) Assessment of hormonal levels in traumatic head injury. <i>International Journal of Pharma and Bio Sciences</i> 3(4): 348-357	- Full text paper not available
Dupuis, C., Thomas, S., Faure, P. et al. (2010) Secondary adrenal insufficiency in the acute phase of pediatric traumatic brain injury. <i>Intensive Care Medicine</i> 36(11): 1906-13	- No comparison between two separate groups of people tested in acute vs. chronic phase
Fernandez-Rodriguez, E., Bernabeu, I., Castro, A. I. et al. (2011) Hypopituitarism following traumatic brain injury: determining factors for diagnosis. <i>Frontiers in Endocrinology</i> 2: 25	- Review article but not a systematic review

Study	Code [Reason]
Giordano, G.; Aimaretti, G.; Ghigo, E. (2005) Variations of pituitary function over time after brain injuries: the lesson from a prospective study. <i>Pituitary</i> 8(34): 227-31	- No comparison between two separate groups of people tested in acute vs. chronic phase
Giuliano, S., Talarico, S., Bruno, L. et al. (2017) Growth hormone deficiency and hypopituitarism in adults after complicated mild traumatic brain injury. <i>Endocrine</i> 58(1): 115-123	- No comparison between two separate groups of people tested in acute vs. chronic phase
Glynn, N. and Agha, A. (2013) Which patient requires neuroendocrine assessment following traumatic brain injury, when and how?. <i>Clinical Endocrinology</i> 78(1): 17-20	- Review article but not a systematic review
Glynn, N. and Agha, A. (2019) The frequency and the diagnosis of pituitary dysfunction after traumatic brain injury. <i>Pituitary</i> 22(3): 249-260	- Review article but not a systematic review
Gupta, P., Mittal, R. S., Sharma, A. et al. (2021) Endocrine Dysfunction in Traumatic Subarachnoid Hemorrhage: A Prospective Study. <i>Indian Journal of Neurosurgery</i> .	- No comparison between two separate groups of people tested in acute vs. chronic phase
Hacioglu, A. and Kelestemur, F. (2019) Neuroendocrine consequences of traumatic brain injury and strategies for its management. <i>Erciyes Medical Journal</i> 41(4): 357-363	- Review article but not a systematic review
Hacioglu, A.; Kelestimur, F.; Tanriverdi, F. (2020) Long-term neuroendocrine consequences of traumatic brain injury and strategies for management. <i>Expert Review of Endocrinology &amp; Metabolism</i> 15(2): 123-139	- Review article but not a systematic review
Hadjizacharia P, Beale EO, Inaba K et al. (2008) Acute diabetes insipidus in severe head injury: a prospective study. <i>Journal of the American College of Surgeons</i> 207(4): 477-484	- No comparison between two separate groups of people tested in acute vs. chronic phase
Hannon, M. J., Crowley, R. K., Behan, L. A. et al. (2013) Acute glucocorticoid deficiency and diabetes insipidus are common after acute traumatic brain injury and predict mortality. <i>Journal of Clinical Endocrinology &amp; Metabolism</i> 98(8): 3229-37	- No comparison between two separate groups of people tested in acute vs. chronic phase
Hari Kumar, K. V.; Swamy, M. N.; Khan, M. A. (2016) Prevalence of hypothalamo pituitary dysfunction in patients of traumatic brain injury.	- No comparison between two separate groups of people tested in acute vs. chronic phase

Study	Code [Reason]
Indian Journal of Endocrinology and Metabolism 20(6): 772-778	
Herrmann, B. L., Rehder, J., Kahlke, S. et al. (2006) Hypopituitarism following severe traumatic brain injury. <i>Experimental &amp; Clinical Endocrinology &amp; Diabetes</i> 114(6): 316-21	- No comparison between two separate groups of people tested in acute vs. chronic phase
Hwang, S. L., Lieu, A. S., Howng, S. L. et al. (1998) Hypothalamic dysfunction in acute head-injured patients with stress ulcer. <i>Kaohsiung Journal of Medical Sciences</i> 14(9): 554-60	- No comparison between two separate groups of people tested in acute vs. chronic phase
Idowu, O. E.; Obafunwa, J. O.; Soyemi, S. O. (2017) Pituitary gland trauma in fatal nonsurgical closed traumatic brain injury. <i>Brain Injury</i> 31(3): 359-362	- No comparison between two separate groups of people tested in acute vs. chronic phase
Ioachimescu, A. G., Hampstead, B. M., Moore, A. et al. (2015) Growth hormone deficiency after mild combat-related traumatic brain injury. <i>Pituitary</i> 18(4): 535-41	- No comparison between two separate groups of people tested in acute vs. chronic phase
Izzo, G., Tirelli, A., Angrisani, E. et al. (2016) Pituitary dysfunction and its association with quality of life in traumatic brain injury. <i>International Journal Of Surgery</i> 28suppl1: S103-8	- No comparison between two separate groups of people tested in acute vs. chronic phase
Jeong, J. H., Kim, Y. Z., Cho, Y. W. et al. (2010) Negative effect of hypopituitarism following brain trauma in patients with diffuse axonal injury. <i>Journal of Neurosurgery</i> 113(3): 532-8	- No comparison between two separate groups of people tested in acute vs. chronic phase
Kelestimur, F. (2009) Growth hormone deficiency after traumatic brain injury in adults: when to test and how to treat?. <i>Pediatric Endocrinology Reviews</i> 6suppl4: 534-9	- No comparison between two separate groups of people tested in acute vs. chronic phase
Kelly, D. F., Chaloner, C., Evans, D. et al. (2014) Prevalence of pituitary hormone dysfunction, metabolic syndrome, and impaired quality of life in retired professional football players: a prospective study. <i>Journal of Neurotrauma</i> 31(13): 1161-71	- No comparison between two separate groups of people tested in acute vs. chronic phase
Kelly, D. F., Gonzalo, I. T., Cohan, P. et al. (2000) Hypopituitarism following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a preliminary report. <i>Journal of Neurosurgery</i> 93(5): 743-52	- No comparison between two separate groups of people tested in acute vs. chronic phase

Study	Code [Reason]
Khadr, S. N., Crofton, P. M., Jones, P. A. et al. (2010) Evaluation of pituitary function after traumatic brain injury in childhood. <i>Clinical Endocrinology</i> 73(5): 637-43	- No comparison between two separate groups of people tested in acute vs. chronic phase
Khajeh, L., Blijdorp, K., Neggers, S. J. et al. (2014) Hypopituitarism after subarachnoid haemorrhage, do we know enough?. <i>BMC neurology</i> 14(1): 205	- Population - excludes traumatic brain injury
Kibayashi, K., Shimada, R., Nakao, K. et al. (2012) Analysis of pituitary lesions in fatal closed head injury. <i>American Journal of Forensic Medicine &amp; Pathology</i> 33(3): 206-10	- No comparison between two separate groups of people tested in acute vs. chronic phase
Kleindienst, A., Brabant, G., Bock, C. et al. (2009) Neuroendocrine function following traumatic brain injury and subsequent intensive care treatment: a prospective longitudinal evaluation. <i>Journal of Neurotrauma</i> 26(9): 1435-46	- No comparison between two separate groups of people tested in acute vs. chronic phase
Klose, M. and Feldt-Rasmussen, U. (2008) Does the type and severity of brain injury predict hypothalamo-pituitary dysfunction? Does post-traumatic hypopituitarism predict worse outcome?. <i>Pituitary</i> 11(3): 255-61	- Review article but not a systematic review
Klose, M., Juul, A., Poulsgaard, L. et al. (2007) Prevalence and predictive factors of post-traumatic hypopituitarism. <i>Clinical Endocrinology</i> 67(2): 193-201	- No comparison between two separate groups of people tested in acute vs. chronic phase
Klose, M., Juul, A., Struck, J. et al. (2007) Acute and long-term pituitary insufficiency in traumatic brain injury: a prospective single-centre study. <i>Clinical Endocrinology</i> 67(4): 598-606	- No comparison between two separate groups of people tested in acute vs. chronic phase
Klose, M., Stochholm, K., Janukonyte, J. et al. (2015) Patient reported outcome in posttraumatic pituitary deficiency: results from The Danish National Study on posttraumatic hypopituitarism. <i>European Journal of Endocrinology</i> 172(6): 753-62	- No comparison between two separate groups of people tested in acute vs. chronic phase
Klose, M., Stochholm, K., Janukonyte, J. et al. (2014) Prevalence of posttraumatic growth hormone deficiency is highly dependent on the diagnostic set-up: results from The Danish National Study on Posttraumatic	- No comparison between two separate groups of people tested in acute vs. chronic phase



Study	Code [Reason]
Hypopituitarism. Journal of Clinical Endocrinology & Metabolism 99(1): 101-10	
Klose, M., Watt, T., Brennum, J. et al. (2007) Posttraumatic hypopituitarism is associated with an unfavorable body composition and lipid profile, and decreased quality of life 12 months after injury. Journal of Clinical Endocrinology & Metabolism 92(10): 3861-8	- No comparison between two separate groups of people tested in acute vs. chronic phase
Kokshoorn, N. E., Smit, J. W., Nieuwlaat, W. A. et al. (2011) Low prevalence of hypopituitarism after traumatic brain injury: a multicenter study. European Journal of Endocrinology 165(2): 225-31	- No comparison between two separate groups of people tested in acute vs. chronic phase
Kokshoorn, N. E., Wassenaar, M. J., Biermasz, N. R. et al. (2010) Hypopituitarism following traumatic brain injury: prevalence is affected by the use of different dynamic tests and different normal values. European Journal of Endocrinology 162(1): 11-8	- Systematic review used as source of primary studies
Kopczak, A., Kilimann, I., von Rosen, F. et al. (2014) Screening for hypopituitarism in 509 patients with traumatic brain injury or subarachnoid hemorrhage. Journal of Neurotrauma 31(1): 99-107	- Compares people assessed at different time-points but outcomes not relevant to review protocol
Kozlowski Moreau, O., Yollin, E., Merlen, E. et al. (2012) Lasting pituitary hormone deficiency after traumatic brain injury. Journal of Neurotrauma 29(1): 81-9	- No comparison between two separate groups of people tested in acute vs. chronic phase
Krahulik, D., Aleksijevic, D., Smolka, V. et al. (2017) Prospective study of hypothalamo-hypophyseal dysfunction in children and adolescents following traumatic brain injury. Biomedical Papers of the Medical Faculty of Palacky University in Olomouc, Czech Republic 161(1): 80-85	- No comparison between two separate groups of people tested in acute vs. chronic phase
Krahulik, D., Zapletalova, J., Frysak, Z. et al. (2010) Dysfunction of hypothalamic-hypophysial axis after traumatic brain injury in adults. Journal of Neurosurgery 113(3): 581-4	- No comparison between two separate groups of people tested in acute vs. chronic phase
Kreber, L. A.; Griesbach, G. S.; Ashley, M. J. (2016) Detection of Growth Hormone Deficiency in Adults with Chronic Traumatic Brain Injury. Journal of Neurotrauma 33(17): 1607-13	- No comparison between two separate groups of people tested in acute vs. chronic phase

Study	Code [Reason]
Krewer, C., Schneider, M., Schneider, H. J. et al. (2016) Neuroendocrine Disturbances One to Five or More Years after Traumatic Brain Injury and Aneurysmal Subarachnoid Hemorrhage: Data from the German Database on Hypopituitarism. <i>Journal of Neurotrauma</i> 33(16): 1544-53	- No comparison between two separate groups of people tested in acute vs. chronic phase
Lauzier, F., Turgeon, A. F., Boutin, A. et al. (2014) Clinical outcomes, predictors, and prevalence of anterior pituitary disorders following traumatic brain injury: a systematic review. <i>Critical care medicine</i> 42(3): 712-21	- Systematic review used as source of primary studies
Leal-Cerro, A., Flores, J. M., Rincon, M. et al. (2005) Prevalence of hypopituitarism and growth hormone deficiency in adults long-term after severe traumatic brain injury. <i>Clinical Endocrinology</i> 62(5): 525-32	- No comparison between two separate groups of people tested in acute vs. chronic phase
Lee, J., Anderson, L. J., Migula, D. et al. (2021) Experience of a Pituitary Clinic for US Military Veterans With Traumatic Brain Injury. <i>Journal of the Endocrine Society</i> 5(4): bvab005	- No comparison between two separate groups of people tested in acute vs. chronic phase
Lee, S. C.; Zasler, N. D.; Kreutzer, J. S. (1994) Male pituitary-gonadal dysfunction following severe traumatic brain injury. <i>Brain Injury</i> 8(6): 571-7	- No comparison between two separate groups of people tested in acute vs. chronic phase
Lieberman, S. A., Oberoi, A. L., Gilkison, C. R. et al. (2001) Prevalence of neuroendocrine dysfunction in patients recovering from traumatic brain injury. <i>Journal of Clinical Endocrinology &amp; Metabolism</i> 86(6): 2752-6	- No comparison between two separate groups of people tested in acute vs. chronic phase
Lithgow, K., Chin, A., Debert, C. T. et al. (2018) Utility of serum IGF-1 for diagnosis of growth hormone deficiency following traumatic brain injury and sport-related concussion. <i>BMC Endocrine Disorders</i> 18(1): 20	- No comparison between two separate groups of people tested in acute vs. chronic phase
Loggini, A., Tangonan, R., El Ammar, F. et al. (2021) Neuroendocrine Dysfunction in the Acute Setting of Penetrating Brain Injury: A Systematic Review. <i>World Neurosurgery</i> 147: 172-180.e1	- Systematic review used as source of primary studies
Lorenzo, M., Peino, R., Castro, A. I. et al. (2005) Hypopituitarism and growth hormone deficiency in adult subjects after traumatic brain injury: who and when to test. <i>Pituitary</i> 8(34): 233-7	- Review article but not a systematic review

Study	Code [Reason]
Maiya, B., Newcombe, V., Nortje, J. et al. (2008) Magnetic resonance imaging changes in the pituitary gland following acute traumatic brain injury. <i>Intensive Care Medicine</i> 34(3): 468-75	- No comparison between two separate groups of people tested in acute vs. chronic phase
Malekpour, B., Mehrafshan, A., Saki, F. et al. (2012) Effect of posttraumatic serum thyroid hormone levels on severity and mortality of patients with severe traumatic brain injury. <i>Acta Medica Iranica</i> 50(2): 113-6	- No comparison between two separate groups of people tested in acute vs. chronic phase
Marina, D., Klose, M., Nordenbo, A. et al. (2015) Early endocrine alterations reflect prolonged stress and relate to 1-year functional outcome in patients with severe brain injury. <i>European Journal of Endocrinology</i> 172(6): 813-22	- No comparison between two separate groups of people tested in acute vs. chronic phase
Masarsky, C. S. (2018) Hypoxic stress: A risk factor for post-concussive hypopituitarism?. <i>Medical Hypotheses</i> 121: 31-34	- Review article but not a systematic review
Medic-Stojanoska, M. (2009) Traumatic brain injury induced hypopituitarism in children and adolescents. <i>Pediatric Health</i> 3(3): 283-291	- Review article but not a systematic review
Mercier, L. J., Kruger, N., Le, Q. B. et al. (2021) Growth hormone deficiency testing and treatment following mild traumatic brain injury. <i>Scientific Reports</i> 11(1): 8534	- No comparison between two separate groups of people tested in acute vs. chronic phase
Moon, R. J., Sutton, T., Wilson, P. M. et al. (2010) Pituitary function at long-term follow-up of childhood traumatic brain injury. <i>Journal of Neurotrauma</i> 27(10): 1827-35	- No comparison between two separate groups of people tested in acute vs. chronic phase
Moro, N., Katayama, Y., Igarashi, T. et al. (2007) Hyponatremia in patients with traumatic brain injury: incidence, mechanism, and response to sodium supplementation or retention therapy with hydrocortisone. <i>Surgical Neurology</i> 68(4): 387-93	- No comparison between two separate groups of people tested in acute vs. chronic phase  - Focus on hyponatremia not hypopituitarism
Nemes, O., Kovacs, N., Czeiter, E. et al. (2015) Predictors of post-traumatic pituitary failure during long-term follow-up. <i>Hormones</i> 14(3): 383-91	- No comparison between two separate groups of people tested in acute vs. chronic phase
Nemes, O., Kovacs, N., Szujó, S. et al. (2016) Can early clinical parameters predict post-traumatic pituitary dysfunction in severe	- No comparison between two separate groups of people tested in acute vs. chronic phase

Study	Code [Reason]
traumatic brain injury?. Acta Neurochirurgica 158(12): 2347-2353	
Niederland, T., Makovi, H., Gal, V. et al. (2007) Abnormalities of pituitary function after traumatic brain injury in children. Journal of Neurotrauma 24(1): 119-27	- No comparison between two separate groups of people tested in acute vs. chronic phase
Nordon, D. G., Guimaraes, R. R., Nigri, A. A. et al. (2012) Mild traumatic brain injury and immediate hypopituitarism in children. Scientia Medica 22(2): 86-90	- No comparison between two separate groups of people tested in acute vs. chronic phase
Norwood, K. W., Deboer, M. D., Gurka, M. J. et al. (2010) Traumatic brain injury in children and adolescents: surveillance for pituitary dysfunction. Clinical Pediatrics 49(11): 1044-9	- No comparison between two separate groups of people tested in acute vs. chronic phase
Ntali, G. and Tsagarakis, S. (2020) Pituitary dysfunction after traumatic brain injury: prevalence and screening strategies. Expert Review of Endocrinology & Metabolism 15(5): 341-354	- Review article but not a systematic review
Ntali, G. and Tsagarakis, S. (2019) Traumatic brain injury induced neuroendocrine changes: acute hormonal changes of anterior pituitary function. Pituitary 22(3): 283-295	- Review article but not a systematic review
Obiols Alfonso, G. (2012) Impact of head trauma on pituitary function. Endocrinologia y Nutricion 59(8): 505-15	- Study not reported in English
Park, K. D., Kim, D. Y., Lee, J. K. et al. (2010) Anterior pituitary dysfunction in moderate-to-severe chronic traumatic brain injury patients and the influence on functional outcome. Brain Injury 24(11): 1330-5	- No comparison between two separate groups of people tested in acute vs. chronic phase
Pavlovic, D., Pekic, S., Stojanovic, M. et al. (2010) Chronic cognitive sequelae after traumatic brain injury are not related to growth hormone deficiency in adults. European Journal of Neurology 17(5): 696-702	- No comparison between two separate groups of people tested in acute vs. chronic phase
Pekic, S. and Popovic, V. (2017) DIAGNOSIS OF ENDOCRINE DISEASE: Expanding the cause of hypopituitarism. European Journal of Endocrinology 176(6): R269-R282	- Review article but not a systematic review

Study	Code [Reason]
<p>Personnier, C., Crosnier, H., Meyer, P. et al. (2014) Prevalence of pituitary dysfunction after severe traumatic brain injury in children and adolescents: a large prospective study. <i>Journal of Clinical Endocrinology &amp; Metabolism</i> 99(6): 2052-60</p>	<p>- No comparison between two separate groups of people tested in acute vs. chronic phase</p>
<p>Popovic, V., Pekic, S., Pavlovic, D. et al. (2004) Hypopituitarism as a consequence of traumatic brain injury (TBI) and its possible relation with cognitive disabilities and mental distress. <i>Journal of Endocrinological Investigation</i> 27(11): 1048-54</p>	<p>- No comparison between two separate groups of people tested in acute vs. chronic phase</p>
<p>Porto, L., Margerkurth, J., Althaus, J. et al. (2011) Morphometry of the pituitary gland and hypothalamus in long-term survivors of childhood trauma. <i>Childs Nervous System</i> 27(11): 1937-41</p>	<p>- No comparison between two separate groups of people tested in acute vs. chronic phase</p>
<p>Powner, D. J., Boccalandro, C., Alp, M. S. et al. (2006) Endocrine failure after traumatic brain injury in adults. <i>Neurocritical Care</i> 5(1): 61-70</p>	<p>- Review article but not a systematic review</p>
<p>Prasanna, K. L.; Mittal, R. S.; Gandhi, A. (2015) Neuroendocrine dysfunction in acute phase of moderate-to-severe traumatic brain injury: a prospective study. <i>Brain Injury</i> 29(3): 336-42</p>	<p>- No comparison between two separate groups of people tested in acute vs. chronic phase</p>
<p>Prodam, F., Gasco, V., Caputo, M. et al. (2013) Metabolic alterations in patients who develop traumatic brain injury (TBI)-induced hypopituitarism. <i>Growth Hormone &amp; Igf Research</i> 23(4): 109-13</p>	<p>- No comparison between two separate groups of people tested in acute vs. chronic phase</p>
<p>Rabelink, N. M., Peeters, G. M., van Schoor, N. M. et al. (2011) Self-reported loss of consciousness after head trauma does not predispose to hypopituitarism in an older population. <i>Journal of Head Trauma Rehabilitation</i> 26(1): 90-7</p>	<p>- No comparison between two separate groups of people tested in acute vs. chronic phase</p> <p>- Population - includes based on self-reported head injury and loss of consciousness which is unreliable</p>
<p>Reifschneider, K.; Auble, B. A.; Rose, S. R. (2015) Update of Endocrine Dysfunction following Pediatric Traumatic Brain Injury. <i>Journal of Clinical Medicine</i> 4(8): 1536-60</p>	<p>- Review article but not a systematic review</p>
<p>Renner, C., Hummelsheim, H., Kopczak, A. et al. (2012) The influence of gender on the injury</p>	<p>- No comparison between two separate groups of people tested in acute vs. chronic phase</p>

Study	Code [Reason]
severity, course and outcome of traumatic brain injury. <i>Brain Injury</i> 26(11): 1360-71	
Salomon-Estebanez, M. A., Grau, G., Vela, A. et al. (2014) Is routine endocrine evaluation necessary after paediatric traumatic brain injury?. <i>Journal of Endocrinological Investigation</i> 37(2): 143-8	- No comparison between two separate groups of people tested in acute vs. chronic phase
Samadani, U.; Reyes-Moreno, I.; Buchfelder, M. (2005) Endocrine dysfunction following traumatic brain injury: mechanisms, pathophysiology and clinical correlations. <i>Acta Neurochirurgica - Supplement</i> 93: 121-5	- Review article but not a systematic review
Sav, A., Rotondo, F., Syro, L. V. et al. (2019) Pituitary pathology in traumatic brain injury: a review. <i>Pituitary</i> 22(3): 201-211	- Review article but not a systematic review
Schneider, H. J., Corneli, G., Kreitschman-Andermahr, I. et al. (2007) Traumatic brain injury and hypopituitarism in children and adolescents: is the problem under-estimated?. <i>Pediatric Endocrinology Reviews</i> 4(3): 205-9	- Review article but not a systematic review
Schneider, H. J., Kreitschmann-Andermahr, I., Ghigo, E. et al. (2007) Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. <i>JAMA</i> 298(12): 1429-38	- Systematic review used as source of primary studies
Schneider, H. J., Samann, P. G., Schneider, M. et al. (2007) Pituitary imaging abnormalities in patients with and without hypopituitarism after traumatic brain injury. <i>Journal of Endocrinological Investigation</i> 30(4): RC9-RC12	- No comparison between two separate groups of people tested in acute vs. chronic phase
Schneider, H. J., Schneider, M., Kreitschmann-Andermahr, I. et al. (2011) Structured assessment of hypopituitarism after traumatic brain injury and aneurysmal subarachnoid hemorrhage in 1242 patients: the German interdisciplinary database. <i>Journal of Neurotrauma</i> 28(9): 1693-8	- Compares people assessed at different time-points but outcomes not relevant to review protocol  - No comparison between two separate groups of people tested in acute vs. chronic phase
Schneider, H. J., Schneider, M., Saller, B. et al. (2006) Prevalence of anterior pituitary insufficiency 3 and 12 months after traumatic brain injury. <i>European Journal of Endocrinology</i> 154(2): 259-65	- No comparison between two separate groups of people tested in acute vs. chronic phase

Study	Code [Reason]
Schneider, M., Schneider, H. J., Yassouridis, A. et al. (2008) Predictors of anterior pituitary insufficiency after traumatic brain injury. <i>Clinical Endocrinology</i> 68(2): 206-12	- No comparison between two separate groups of people tested in acute vs. chronic phase
Silva, P. P., Bhatnagar, S., Herman, S. D. et al. (2015) Predictors of Hypopituitarism in Patients with Traumatic Brain Injury. <i>Journal of Neurotrauma</i> 32(22): 1789-95	- No comparison between two separate groups of people tested in acute vs. chronic phase
Soliman, A. T., Adel, A., Soliman, N. A. et al. (2015) Pituitary Deficiency Following Traumatic Brain Injury in Early Childhood: A Review of the Literature. <i>Georgian Medical News</i> : 62-71	- Review article but not a systematic review
Su, D. H.; Chang, Y. C.; Chang, C. C. (2005) Post-traumatic anterior and posterior pituitary dysfunction. <i>Journal of the Formosan Medical Association</i> 104(7): 463-7	- No comparison between two separate groups of people tested in acute vs. chronic phase
Tan, C. L., Alavi, S. A., Baldeweg, S. E. et al. (2017) The screening and management of pituitary dysfunction following traumatic brain injury in adults: British Neurotrauma Group guidance. <i>Journal of Neurology, Neurosurgery &amp; Psychiatry</i> 88(11): 971-981	- Systematic review used as source of primary studies
Tan, C. L. and Hutchinson, P. J. (2019) A neurosurgical approach to traumatic brain injury and post-traumatic hypopituitarism. <i>Pituitary</i> 22(3): 332-337	- Systematic review used as source of primary studies
Tanriverdi, F., De Bellis, A., Ulutabanca, H. et al. (2013) A five year prospective investigation of anterior pituitary function after traumatic brain injury: is hypopituitarism long-term after head trauma associated with autoimmunity?. <i>Journal of Neurotrauma</i> 30(16): 1426-33	- No comparison between two separate groups of people tested in acute vs. chronic phase
Tanriverdi, F., Senyurek, H., Unluhizarci, K. et al. (2006) High risk of hypopituitarism after traumatic brain injury: a prospective investigation of anterior pituitary function in the acute phase and 12 months after trauma. <i>Journal of Clinical Endocrinology &amp; Metabolism</i> 91(6): 2105-11	- No comparison between two separate groups of people tested in acute vs. chronic phase
Tanriverdi, F., Taheri, S., Ulutabanca, H. et al. (2008) Apolipoprotein E3/E3 genotype decreases the risk of pituitary dysfunction after traumatic brain injury due to various causes:	- No comparison between two separate groups of people tested in acute vs. chronic phase

Study	Code [Reason]
preliminary data. Journal of Neurotrauma 25(9): 1071-7	
Tanriverdi, F., Ulutabanca, H., Unluhizarci, K. et al. (2008) Three years prospective investigation of anterior pituitary function after traumatic brain injury: a pilot study. Clinical Endocrinology 68(4): 573-9	- No comparison between two separate groups of people tested in acute vs. chronic phase
Tanriverdi, F., Ulutabanca, H., Unluhizarci, K. et al. (2007) Pituitary functions in the acute phase of traumatic brain injury: are they related to severity of the injury or mortality?. Brain Injury 21(4): 433-9	- No comparison between two separate groups of people tested in acute vs. chronic phase
Tanriverdi, F.; Unluhizarci, K.; Kelestimur, F. (2010) Pituitary function in subjects with mild traumatic brain injury: a review of literature and proposal of a screening strategy. Pituitary 13(2): 146-53	- Systematic review used as source of primary studies
Tolli, A., Borg, J., Bellander, B. M. et al. (2017) Pituitary function within the first year after traumatic brain injury or subarachnoid haemorrhage. Journal of Endocrinological Investigation 40(2): 193-205	- No comparison between two separate groups of people tested in acute vs. chronic phase
Tritos, N. A., Yuen, K. C., Kelly, D. F. et al. (2015) American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: A Neuroendocrine Approach to Patients with Traumatic Brain Injury. Endocrine Practice 21(7): 823-31	- Review article but not a systematic review
Ulfarsson, T., Arnar Gudnason, G., Rosen, T. et al. (2013) Pituitary function and functional outcome in adults after severe traumatic brain injury: the long-term perspective. Journal of Neurotrauma 30(4): 271-80	- No comparison between two separate groups of people tested in acute vs. chronic phase
Ulutabanca, H., Hatipoglu, N., Karaca, Z. et al. (2013) Evaluation of TSH and ACTH hormone levels during the acute phase after traumatic brain injury in pediatric cases. Erciyes Tip Dergisi 35(3): 128-131	- Study not reported in English
Ulutabanca, H., Hatipoglu, N., Tanriverdi, F. et al. (2014) Prospective investigation of anterior pituitary function in the acute phase and 12 months after pediatric traumatic brain injury. Childs Nervous System 30(6): 1021-8	- No comparison between two separate groups of people tested in acute vs. chronic phase



Study	Code [Reason]
Undurti, A., Colasurdo, E. A., Sikkema, C. L. et al. (2018) Chronic Hypopituitarism Associated with Increased Postconcussive Symptoms Is Prevalent after Blast-Induced Mild Traumatic Brain Injury. <i>Frontiers in neurology</i> [electronic resource]. 9: 72	- No comparison between two separate groups of people tested in acute vs. chronic phase
Urban, R. J.; Harris, P.; Masel, B. (2005) Anterior hypopituitarism following traumatic brain injury. <i>Brain Injury</i> 19(5): 349-58	- Review article but not a systematic review
van der Eerden, A. W., Twickler, M. T., Sweep, F. C. et al. (2010) Should anterior pituitary function be tested during follow-up of all patients presenting at the emergency department because of traumatic brain injury?. <i>European Journal of Endocrinology</i> 162(1): 19-28	- No comparison between two separate groups of people tested in acute vs. chronic phase
Wachter, D., Gundling, K., Oertel, M. F. et al. (2009) Pituitary insufficiency after traumatic brain injury. <i>Journal of Clinical Neuroscience</i> 16(2): 202-8	- No comparison between two separate groups of people tested in acute vs. chronic phase
Wagner, J., Dusick, J. R., McArthur, D. L. et al. (2010) Acute gonadotroph and somatotroph hormonal suppression after traumatic brain injury. <i>Journal of Neurotrauma</i> 27(6): 1007-19	- No comparison between two separate groups of people tested in acute vs. chronic phase
West, A. N.; Diaz-Thomas, A. M.; Shafi, N. I. (2020) Evidence Limitations in Determining Sexually Dimorphic Outcomes in Pediatric Post-Traumatic Hypopituitarism and the Path Forward. <i>Frontiers in neurology</i> [electronic resource]. 11: 551923	- Review article but not a systematic review
Yang, W. H., Chen, P. C., Wang, T. C. et al. (2016) Endocrine dysfunction following traumatic brain injury: a 5-year follow-up nationwide-based study. <i>Scientific Reports</i> 6: 32987	- No comparison between two separate groups of people tested in acute vs. chronic phase
You, W., Zhu, Y., Wen, L. et al. (2019) Risk Factors for Anterior Hypopituitarism in Patients With Traumatic Brain Injury. <i>Journal of Craniofacial Surgery</i> 30(7): 2119-2123	- No comparison between two separate groups of people tested in acute vs. chronic phase
Zheng, P., He, B., Guo, Y. et al. (2015) Decreased apparent diffusion coefficient in the pituitary and correlation with hypopituitarism in patients with traumatic brain injury. <i>Journal of Neurosurgery</i> 123(1): 75-80	- No comparison between two separate groups of people tested in acute vs. chronic phase

<b>Study</b>	<b>Code [Reason]</b>
Zheng, P.; He, B.; Tong, W. (2014) Dynamic pituitary hormones change after traumatic brain injury. <i>Neurology India</i> 62(3): 280-4	- No comparison between two separate groups of people tested in acute vs. chronic phase

7

8 **Health Economic studies**

9 Published health economic studies that met the inclusion criteria (relevant population,  
10 comparators, economic study design, published 2006 or later and not from non-OECD  
11 country or USA) but that were excluded following appraisal of applicability and  
12 methodological quality are listed below. See the health economic protocol for more details.

13 None.

14

## 15 Appendix K – Research recommendations – full details

### K.14 Research recommendation

17 When should people with head injury be investigated for hypopituitarism?

#### K.181 Why this is important

19 At present, lack of data means that a proportion of people who have traumatic brain injury  
 20 are not diagnosed with endocrinopathy/hypopituitarism arising from the initial injury.  
 21 Presenting symptoms are insidious in onset and not readily recognised by medical  
 22 practitioners, leading to delayed or missed diagnoses and therefore suboptimal treatment. In  
 23 turn, this may increase the burden of morbidity and reduce health related quality of life.  
 24 Research to identify early and accurate endocrinopathy will lead to improved discharge  
 25 procedures from the hospital, suitable follow up arrangements and enhanced patient  
 26 satisfaction.

#### K.172 Rationale for research recommendation

Importance to ‘patients’ or the population	Research to identify early and accurate endocrinopathy will lead to improved discharge procedures from the hospital, suitable follow up arrangements and enhanced patient satisfaction.
Relevance to NICE guidance	Understanding the natural history of traumatic brain injury will be crucial to the planning of pathways of care. This will enable the development of NICE guidance that will identify people who are likely to require endocrine follow up, estimate the risk and timing of hypopituitarism and provide advice to medical practitioners and people with traumatic brain injury to optimise outcomes of care.
Relevance to the NHS	Future NICE guidance in traumatic brain injury will prioritise people for admission and discharge and therefore positively impact on patient flow, encourage home management where possible and provide confidence in follow up arrangements for prompt recognition of slowly evolving and delayed presentations of hypopituitarism. In the short term, this will have training and learning implications for NHS staff including those in A&E and in GP practice but in the long run will be beneficial to the provision of inpatient capacity, appropriate radiology investigations, prioritisation of virtual and in-person outpatient consultations and prediction of disability.
National priorities	No National Service Framework or white paper identified but this does not detract from priority as brain injury in children and adults is a public health problem worldwide.
Current evidence base	No evidence was identified
Equality considerations	The research recommendation is relevant to groups of people who live with health

28

inequalities and those with disabilities limiting their access to optimal healthcare.

### K.13 Modified PICO table

<p>Population</p>	<p>Inclusion: Infants, children and adults with head injury who are being screened for hypopituitarism:</p> <ul style="list-style-type: none"> <li>• Adults (aged ≥16 years)</li> <li>• Children (aged ≥1 to &lt;16 years)</li> <li>• Infants (aged &lt;1 year)</li> </ul> <p>Mixed population studies will be included but downgraded for indirectness. Cut-off of 60% will be used for all age groups.</p> <p>Include all severities and stratify by GCS severity:</p> <ul style="list-style-type: none"> <li>• Mild GCS 13-15</li> <li>• Moderate 9-12</li> <li>• Severe GCS 3-8</li> </ul> <p>Exclusion: Adults and children (including infants under 1 year) with superficial injuries to the eye or face without suspected or confirmed head or brain injury.</p>
<p>Intervention</p>	<p>Investigation for hypopituitarism in acute phase</p> <p>Strata:</p> <ol style="list-style-type: none"> <li>1. In ED</li> <li>2. Admission in hospital but not in ED</li> <li>3. After discharge, within 1 year of injury</li> </ol> <p>All timepoints are relevant for investigations for hypopituitarism</p> <p>Diagnostic testing for hypopituitarism: Basal Pituitary investigations are typically similar at the time of presentation and 1 year later. These are generally: electrolytes, cortisol + ACTH, IGF-I, Prolactin, thyroid function, and sex hormones in adults (LH, FSH, oestrogen or testosterone). Depending on the circumstances, some centres might want to do a synacthen instead of random cortisol + ACTH.</p> <p>In children, there is a case to investigate growth failure. For this, a dynamic function test may be required at the 1 year mark. Adults may also have growth hormone deficiency caused by traumatic brain injury and would require dynamic stimulation tests. Any deficiency would require subsequent treatment with growth hormone replacement.</p>

Comparison	Investigation for hypopituitarism in chronic phase: ≥1 year after injury
Outcome	<p>All outcomes are considered equally important for decision making and therefore have all been rated as critical:</p> <ul style="list-style-type: none"> <li>• Mortality</li> <li>• Quality of life (all validated quality of life scores).</li> <li>• Need for treatment of hypopituitarism (growth rate for children will be covered here)</li> <li>• Time to treatment of hypopituitarism</li> <li>• Return to work/return to school</li> </ul> <p>Outcomes should enable cost effectiveness to be evaluated for example to include the incidence of hypopituitarism at different time points.</p> <p>Same outcomes applicable to both adults and children.</p> <p>All-follow-up times will be considered.</p>
Study design	<p>Randomised controlled trials or prospective cohort study:</p> <p>Key confounders:</p> <p>Adults:</p> <ul style="list-style-type: none"> <li>• Extent of extra cranial injury (other organ support)</li> </ul> <p>Children:</p> <ul style="list-style-type: none"> <li>• Extent of extra cranial injury (other organ support)</li> <li>• Age (in children- young child not in adults)</li> </ul>
Timeframe	Medium term – to be completed before the next update of this guidance
Additional information	None